AstraZeneca’s Camille Hertzka Addresses rPFS in mCRPC
Maggie L. Shaw
Camille Hertzka, vice president, head of oncology, US Medical, AstraZeneca, clarifies testing for the HRR mutation in metastatic castrate-resistant prostate cancer (mCRPC) and the predictive importance of radiographic progression-free survival (rPFS) for overall survival in this setting.
Camille Hertzka, vice president, head of oncology, US Medical, AstraZeneca, clarifies testing for the HRR mutation in metastatic castrate-resistant prostate cancer (mCRPC) and the predictive importance of radiographic progression-free survival (rPFS) for overall survival in this setting.
Transcript
Could Lynparza’s approval in mCRPC in the first-line setting translate to fewer unnecessary tests?
Will providers want to see overall survival data or wait longer before Lynparza becomes widely accepted?
Overall survival [OS] is a very important end point, as it’s the gold standard at the end. That’s what we’re all aiming to achieve. Radiographic progression-free survival is used really as a primary end point in most trials in first-line metastatic castrate-resistant prostate cancer because we know OS can take time to assess, can be challenging sometimes also with multiple lines of treatments, and we don’t want to delay potential access to impactful medicine while waiting for OS. Radiographic progression-free survival is really an important point and is recognized as being predictive for OS in most cases.
So I think, looking at the benefits that we’ve seen with PROpel in rPFS and the very positive feedback as the longest median PFS observed in the setting, it’s probably going to be really important to focus on these end points to start with. We know that US data from PROpel are still immature; they will come at a later point, but for now they’re still immature. However, with that, we have been able to see positive trends. And I think it’s also important to remember is that we’ve reported some additional secondary end points, as second disease progression, which is a key secondary end point, which can in most cases predict OS benefits.
So, the positive trends that we see in OS are very reassuring. The strong median PFS that we see is also very reassuring, and as it’s all consistent between primary and secondary end points, we are relatively confident in these outcomes.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Promising Early Efgartigimod Response Data for Generalized Myasthenia Gravis
September 18th 2025
- Iron Dysregulation Linked to MS Progression, Review Finds
September 18th 2025
- Metabolic Issues More Common in Patients With HIV
September 18th 2025
- Barriers to Gender-Affirming Surgery Persist Despite High Satisfaction Rate
September 18th 2025